3PDQ: Primary Parkinsonian Pain Diagnostic Questionnaire: Development and Validation of This Questionnaire

Sponsor
University Hospital, Toulouse (Other)
Overall Status
Recruiting
CT.gov ID
NCT03940872
Collaborator
(none)
200
10
1
24.3
20
0.8

Study Details

Study Description

Brief Summary

Development and validation of a diagnosis questionnaire of parkinsonian primary pain: the "Primary Parkinsonian Pain Diagnostic Questionnaire" (3PDQ)

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Self-questionnaire 3PDQ
N/A

Detailed Description

The aim of this study is to develop and validate a French self-questionnaire to diagnose parkinsonian primary : the "Primary Parkinsonian Pain Diagnostic Questionnaire" (3PDQ). It will allow clinicians to distinguish this pain from the other pain of the parkinsonian patient (whether or not related to Parkinson's disease).

The development and validation of the 3PDQ self-questionnaire will take place in 3 sequential steps:

  1. design of the self-questionnaire

  2. appearance validity study

  3. validation of the self-questionnaire

Participants :

Appearance validity study: 40 painful parkinsonian patients Validation study: 200 painful parkinsonian patients (10 patients per item)

Duration of the study :
Duration of the inclusion period:
  • Appearance validity study : 6 months

  • Validity study : 20 months

Duration of participation for each patient:
  • Appearance validity study : about 30 min

  • Validity study : 3 days maximum Total duration of the study: (with results analysis): 3 years

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Development and Validation of a Diagnosis Questionnaire of Primary Parkinsonian Pain: the 3 PDQ Primary Parkinsonian Pain Diagnostic Questionnaire
Actual Study Start Date :
Apr 23, 2019
Anticipated Primary Completion Date :
May 1, 2021
Anticipated Study Completion Date :
May 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: 3PDQ self-questionnaire validation

200 patients will be included for this step in 10 French Parkinson expert centers.

Diagnostic Test: Self-questionnaire 3PDQ
Visit 1 : - The patient will have to complete the 3PDQ self-questionnaire. - The investigator will conduct an interrogation and a neurological examination in order to ask or not the diagnosis of parkinsonian primary pain, without knowing the result of the 3PDQ. Visit 2 : - The patient will have to complete the 3PDQ self-questionnaire. - An investigator, obligatorily different from the investigator of the visit 1, will conduct to the same interrogation and the same neurological examination in order to ask or not the diagnosis of parkinsonian primary pain, without knowing the result of the 3PDQ. Visits 1 and 2 can be made on the same day. In this case the patient will fill the 3PDQ self questionnaire only once.

Outcome Measures

Primary Outcome Measures

  1. Primary Parkinsonian Pain Questionnaire (3PDQ questionnaire) [4 months]

    Develop and validate a French self-questionnaire to diagnose parkinsonian primary pain, this symptom questionnaire will be called 3PDQ for Primary Parkinsonian Pain Questionnaire. This questionnaire present 5 items: Location of the most embarrassing pain, Characteristics of pain, if the pain is associated in the same area with one or more of the symptoms, by what is the pain caused or increased, what criteria does the pain correspond to. It is sufficient for each item to check the corresponding boxes

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with Parkinson Disease (PD)

  • Patients who have chronic pain (for at least 3months) moderate to severe (intensity ≥ 4/10 on visual analogue scale from 0 to 10) specific or unspecific to PD

  • Patients who have one type of pain or different type of pain: in this case, patients should suffered from one predominant pain and be able to identify it

  • Patients who have stable analgesic medication during the study

  • Patients who understand and speak fluently French

  • Patients with health insurance

  • Patients who signed the written informed consent form

Exclusion Criteria:
  • Patients with severe depression according to Diagnostic and Statistical Manual (DSM) V criteria

  • Analgesic medication modified recently (less than 1month)

  • Patients with psycho-actives substances or alcohol abused

  • Patients with cognitive impairment (MoCA score < 25)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Neurology service Clermont-Ferrand France
2 Neurology service Lille France
3 Neurology service Lyon France
4 Neurology service Marseille France
5 Neurology Service Montpellier France
6 Neurolgoy service Nancy France
7 Neurology service Nantes France
8 Neurology service Rouen France
9 Neurology service Strasbourg France
10 Neurology service Toulouse France 31059

Sponsors and Collaborators

  • University Hospital, Toulouse

Investigators

  • Principal Investigator: Christine BREFEL COURBON, MCU PH, Service de Pharmacologie Clinique et Service de Neurologie B8

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Toulouse
ClinicalTrials.gov Identifier:
NCT03940872
Other Study ID Numbers:
  • RC 31/18/0034
First Posted:
May 7, 2019
Last Update Posted:
Nov 20, 2020
Last Verified:
Nov 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Toulouse
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 20, 2020